Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...
In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection ...
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric Balloon, a swallowable, procedureless intragastric balloon, in adults with obesity.
In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...
"Because most people with obesity have elevated insulin levels, they develop insulin resistance, which contributes to weight gain. Semaglutide (or Ozempic) helps lower the levels of this fat-storing ...
New anti-obesity drugs should meet a minimum level of weight loss to be considered for approval, the FDA said ...
Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback